- Home
- INCY vs BNT Comparison
INCY vs BNT Comparison
Compare INCY & BNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- BNT
- Stock Information
- Founded
- INCY 1991
- BNT 2020
- Country
- INCY United States
- BNT Bermuda
- Employees
- INCY N/A
- BNT N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- BNT
- Sector
- INCY Health Care
- BNT
- Exchange
- INCY Nasdaq
- BNT Nasdaq
- Market Cap
- INCY 13.0B
- BNT 15.0B
- IPO Year
- INCY 1993
- BNT N/A
- Fundamental
- Price
- INCY $86.92
- BNT $65.64
- Analyst Decision
- INCY Buy
- BNT
- Analyst Count
- INCY 20
- BNT 0
- Target Price
- INCY $79.06
- BNT N/A
- AVG Volume (30 Days)
- INCY 1.9M
- BNT 9.6K
- Earning Date
- INCY 07-29-2025
- BNT 08-07-2025
- Dividend Yield
- INCY N/A
- BNT 0.55%
- EPS Growth
- INCY 900.04
- BNT N/A
- EPS
- INCY 4.37
- BNT 2.78
- Revenue
- INCY $4,584,996,000.00
- BNT $14,371,000,000.00
- Revenue This Year
- INCY $13.53
- BNT N/A
- Revenue Next Year
- INCY $10.38
- BNT N/A
- P/E Ratio
- INCY $19.90
- BNT $23.52
- Revenue Growth
- INCY 18.87
- BNT 57.06
- 52 Week Low
- INCY $53.56
- BNT $43.69
- 52 Week High
- INCY $87.06
- BNT $68.87
- Technical
- Relative Strength Index (RSI)
- INCY 80.83
- BNT N/A
- Support Level
- INCY $76.45
- BNT N/A
- Resistance Level
- INCY $79.43
- BNT N/A
- Average True Range (ATR)
- INCY 2.57
- BNT 0.00
- MACD
- INCY 1.01
- BNT 0.00
- Stochastic Oscillator
- INCY 99.13
- BNT 0.00
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About BNT Brookfield Wealth Solutions Ltd.
Brookfield Wealth Solutions Ltd, formerly Brookfield Reinsurance Ltd operates a capital solutions business providing insurance and reinsurance services to individuals and institutions. Through its subsidiary, the company offers a broad range of insurance products and services, including life insurance and annuities, and personal and commercial property and casualty insurance. It is organized into three reporting segments: Direct Insurance, Reinsurance, and Pension Risk Transfer (PRT).